CSPHF News and Press, CStone Pharmaceuticals - Ordinary Shares From 07/17/22

Qiming Venture Partners closed two new China healthcare and technology funds with $3.2 billion in fresh capital, both of them at their hard cap limits. Suzhou CStone Pharma announced that Gavreto® (pralsetinib) was approved in Hong Kong to treat adult patients with RET fusion-pos...

Blueprint Medicines ( NASDAQ: BPMC ), CStone Pharmaceuticals ( OTCPK:CSPHF ) and Roche's ( OTCQX:RHHBY ) ( OTCQX:RHHBF ) Gavreto was approved in Hong Kong for certain patients with non-small cell lung cancer (NSCLC). CStone said the the new drug a...

Shanghai Fosun Pharma will pay $158 million to acquire a 60% stake in a Singapore oncology medical center chain, Oncocare Medical Pte. OnCusp Therapeutics, a New York-Shanghai biopharma, acquired global rights (ex-China) to a pre-clinical CDH6 antibody drug conjugate from Multitude Th...

CStone brought four products to market last year, and its losses have surged due to growing R&D and sales spending. Appointment of chairman with close ties to WuXi AppTec reveals a power struggle between shareholders and management. Only time will tell whether CStone can impro...

China’s leading biotechnology and other health care companies have continued to grow revenues rapidly over the past two years and are expected to see strong growth in the years to come. Recently, concerns over domestic regulation, increased domestic competition, US Food and Dru...

Company’s four drug approvals in a year will contribute major revenue, but will also challenge CStone’s ability to commercialize its products. Its rollout of four new drugs will be a major test of CStone’s commercialization ability, prompting it to set up an in-ho...

A US FDA oncology advisory panel rejected the NDA submitted by Innovent and Lilly for their partnered anti-PD-1 antibody, voting 14-1 against approval. Hangzhou's Huadong Medicine acquired Asia-Pacific (ex-Japan) rights to a bi-functional immunotherapy from Akso Biopharma of Menlo Par...

BeiGene out-licensed ex-China rights for its TIGIT inhibitor to Novartis in a multi-faceted $2.8 billion deal. As part of the agreement, BeiGene will have rights to market five Novartis oncology drugs in China outside of China's largest cities. Shanghai Ji Xing Pharma in-licensed Chin...

In these troubled times of U.S.-China tensions, sometimes being a copycat has its benefits. The vast majority of the many publicly listed drug makers in China are essentially copycats that license mature drugs from other, mostly western, developers to sell in China. The big news c...

Broncus Holding, a Hangzhou pulmonary medical device company, completed a $200 million IPO on the Hong Kong exchange that valued the company at nearly $1.3 billion. Suzhou CStone Pharma and US-based EQRx reported their partnered PD-(L)1 antibody increased median progression-free survi...